Recommended use: a dose of = 10 mg FloraGLO® Lutein and 2 mg OPTISHARP™ Natural Zeaxanthin is considered efficacious.
Actilease® is a Registered Trademark of DSM Nutritional Products Ltd.
*Kemin has a blue light patent covering three conditions for people of all ages; presbyopia, hyperopia, and astigmatism.
These statements have not been evaluated by the US Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
The information on this webpage is a business-to-business information and not intended for the final consumer. Certain statements may not be applicable in all geographical regions. Product labeling and associated claims differs based upon government requirements and country or region specific information should also be considered when labeling or advertising to final consumers.
This web page and its associated brochures and other documents do not constitute or provide scientific or medical advice, diagnosis, or treatment and are distributed without warranty of any kind, either expressly or implied. This web page, its title or contents and associated brochures and other documents do not in any way make recommendations for health or marketing claims by the reader. Country and region specific regulations should be considered in this regard. Each claim or statement about the effectiveness of Kemin products and/or each claim or statement comparing the effectiveness of Kemin products to the effectiveness of other products is expressly limited to the United States, unless otherwise disclosed on the Kemin websites.
- PubMed, 2018.
- Based on the results of the IQVIA IMS National Disease and Therapeutic Index (NDTI) syndicated report among physicians who recommend a dietary supplement with lutein for eye health through between June 1, 2017 to May 31, 2018.
- Roberts, Richard. “Methods of Treating Ocular Disorders.” Kemin Industries, Inc., assignee. Patent US9226940 B2. 5 Jan. 2016.
- U.S. Food & Drug Administration, 2004. GRAS Notice Inventory, GRN No. 140, 221 and 390.